Evidence map›Paper›PMID 41028306›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Total RNA-seq as a Tool to Study DMD Splicing and Transcriptional Dynamics.

Diane M Dunn, Robert B Weiss

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Diane M DunnDepartment of Human Genetics, University of Utah, Salt Lake City, UT, USA.
Robert B WeissDepartment of Human Genetics, University of Utah, Salt Lake City, UT, USA. bob.weiss@genetics.utah.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in RNA analysis of dystrophin (DMD) mutations have been significantly influenced by improvements in methods to study mRNA transcription and splicing. Early breakthroughs, such as the 1988 cDNA sequencing of the 14-kb muscle transcript isoform of the dystrophin gene, paved the way for RNA-based mutation detection via RT-PCR. These studies revealed that point mutations often cause premature polypeptide chain termination, and RNA polymerase requires approximately 16 h to transcribe the 2.1 Mb Dp427m transcription unit. Next-generation technologies for RNA sequencing (RNA-seq) have enabled broader and more quantitative transcriptome analysis of the DMD locus. This protocol outlines an RNA-seq approach using rRNA depletion to examine muscle biopsy total RNA from DMD/BMD patients, specifically focusing on resolving pseudoexon and other intronic mutations. While not achieving the ultra-deep read depths of targeted RNA-seq methods, this cost-effective strategy provides sufficient coverage to robustly evaluate DMD exon and intron mRNA levels, generating data with comparable read depths for both.

Indexed as

DystrophinMuscular Dystrophy, DuchenneRNA-SeqRNA SplicingTranscription, GeneticExonsGene Expression ProfilingHigh-Throughput Nucleotide SequencingHumansIntronsMutationRNA, MessengerDMD protein, humanDystrophinRNA, MessengerComplex DMD mutationsDystrophinopathyPseudoexonsRNA-seqSplicingTranscription termination

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.